{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:52:40Z","timestamp":1785786760826,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"DOI":"10.1007\/s10585-025-10333-6","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:08:39Z","timestamp":1739164119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The clinical benefit of adding radiotherapy to ipilimumab in patients with melanoma brain metastasis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-6925","authenticated-orcid":false,"given":"Mohammad Amin","family":"Habibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6964-8101","authenticated-orcid":false,"given":"Pouria","family":"Delbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2174-5752","authenticated-orcid":false,"given":"Farhang","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bardia","family":"Hajikarimloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6408-9223","authenticated-orcid":false,"given":"Ali","family":"Allahdadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9489-6869","authenticated-orcid":false,"given":"Saghar","family":"Rouzrokh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shahir Eftekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2537-3279","authenticated-orcid":false,"given":"Adrina","family":"Habibzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-0306","authenticated-orcid":false,"given":"Amir","family":"Khanmirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3694-6863","authenticated-orcid":false,"given":"Pouya","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8862-0778","authenticated-orcid":false,"given":"Ibrahim","family":"Mohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ahmad","family":"Naseri Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"1","key":"10333_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","volume":"88","author":"JH Sampson","year":"1998","unstructured":"Sampson JH et al (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88(1):11\u201320","journal-title":"J Neurosurg"},{"issue":"6","key":"10333_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cam4.140","volume":"2","author":"AW Silk","year":"2013","unstructured":"Silk AW et al (2013) Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2(6):899\u2013906","journal-title":"Cancer Med"},{"key":"10333_CR3","doi-asserted-by":"crossref","unstructured":"Johnson JM et al (2023) Nivolumab and Ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. J Immunother Cancer, 11(8)","DOI":"10.1136\/jitc-2023-007141"},{"key":"10333_CR4","doi-asserted-by":"publisher","first-page":"959289","DOI":"10.3389\/fmed.2022.959289","volume":"9","author":"M Rubatto","year":"2022","unstructured":"Rubatto M et al (2022) Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. Front Med (Lausanne) 9:959289","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10333_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal RD et al (2017) Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 101(1):38\u201344","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10333_CR6","doi-asserted-by":"publisher","first-page":"330e","DOI":"10.1097\/PRS.0000000000002367","volume":"138","author":"SN Pavri","year":"2016","unstructured":"Pavri SN et al (2016) Malignant melanoma: beyond the basics. Plast Reconstr Surg 138(2):330e\u2013340e","journal-title":"Plast Reconstr Surg"},{"issue":"2","key":"10333_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11060-021-03768-w","volume":"153","author":"D Sheehan","year":"2021","unstructured":"Sheehan D, Sheehan K, Sheehan J (2021) Sonodynamic therapy for metastatic melanoma to the brain. J Neurooncol 153(2):373\u2013374","journal-title":"J Neurooncol"},{"issue":"8","key":"10333_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA et al (2018) Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the brain. N Engl J Med 379(8):722\u2013730","journal-title":"N Engl J Med"},{"issue":"10","key":"10333_CR9","first-page":"1312","volume":"17","author":"KR Patel","year":"2015","unstructured":"Patel KR et al (2015) Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neurooncology 17(10):1312\u20131321","journal-title":"Neurooncology"},{"key":"10333_CR10","doi-asserted-by":"crossref","unstructured":"Amaral T et al (2020) Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. J Immunother Cancer, 8(1)","DOI":"10.1136\/jitc-2019-000333"},{"issue":"4","key":"10333_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3857\/roj.2016.02033","volume":"34","author":"T Koo","year":"2016","unstructured":"Koo T, Kim IA (2016) Radiotherapy and immune checkpoint blockades: a snapshot in 2016. Radiation Oncol J 34(4):250","journal-title":"Radiation Oncol J"},{"key":"10333_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ctro.2017.12.004","volume":"9","author":"R Chicas-Sett","year":"2018","unstructured":"Chicas-Sett R et al (2018) Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: a systematic review. Clin Translational Radiation Oncol 9:5\u201311","journal-title":"Clin Translational Radiation Oncol"},{"key":"10333_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"10333_CR14","doi-asserted-by":"crossref","unstructured":"Deeks JJ et al (2019) Analysing data and undertaking meta-analyses, in Cochrane Handbook for Systematic Reviews of Interventions. pp. 241\u2013284","DOI":"10.1002\/9781119536604.ch10"},{"issue":"6","key":"10333_CR15","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/CMR.0b013e32834d3d88","volume":"21","author":"JS Weber","year":"2011","unstructured":"Weber JS et al (2011) Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21(6):530\u2013534","journal-title":"Melanoma Res"},{"issue":"9","key":"10333_CR16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1470-2045(12)70324-8","volume":"13","author":"AM Di Giacomo","year":"2012","unstructured":"Di Giacomo AM et al (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13(9):879\u2013886","journal-title":"Lancet Oncol"},{"issue":"5","key":"10333_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459\u2013465","journal-title":"Lancet Oncol"},{"issue":"2","key":"10333_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","volume":"117","author":"JP Knisely","year":"2012","unstructured":"Knisely JP et al (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117(2):227\u2013233","journal-title":"J Neurosurg"},{"issue":"3","key":"10333_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/CMR.0b013e32835f3d90","volume":"23","author":"M Mathew","year":"2013","unstructured":"Mathew M et al (2013) Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23(3):191\u2013195","journal-title":"Melanoma Res"},{"issue":"1","key":"10333_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11060-014-1400-y","volume":"118","author":"P Queirolo","year":"2014","unstructured":"Queirolo P et al (2014) Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 118(1):109\u2013116","journal-title":"J Neurooncol"},{"issue":"1","key":"10333_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2340\/00015555-1654","volume":"94","author":"MP Konstantinou","year":"2014","unstructured":"Konstantinou MP et al (2014) Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. Acta Derm Venereol 94(1):45\u201349","journal-title":"Acta Derm Venereol"},{"key":"10333_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-015-0095-8","volume":"3","author":"JD Schoenfeld","year":"2015","unstructured":"Schoenfeld JD et al (2015) Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer 3:50","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10333_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11060-014-1617-9","volume":"121","author":"NK Gerber","year":"2015","unstructured":"Gerber NK et al (2015) Ipilimumab and whole brain radiation therapy for melanoma brain metastases. J Neurooncol 121(1):159\u2013165","journal-title":"J Neurooncol"},{"issue":"2","key":"10333_CR24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","volume":"92","author":"AP Kiess","year":"2015","unstructured":"Kiess AP et al (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92(2):368\u2013375","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10333_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cam4.315","volume":"4","author":"K Tazi","year":"2015","unstructured":"Tazi K et al (2015) Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 4(1):1\u20136","journal-title":"Cancer Med"},{"issue":"1","key":"10333_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1684\/ejd.2014.2471","volume":"25","author":"F Chasset","year":"2015","unstructured":"Chasset F et al (2015) Single-center study under a French Temporary authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. Eur J Dermatol 25(1):36\u201344","journal-title":"Eur J Dermatol"},{"issue":"3","key":"10333_CR27","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2014.12.FOCUS14698","volume":"38","author":"PS Jones","year":"2015","unstructured":"Jones PS et al (2015) Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. Neurosurg Focus 38(3):E5","journal-title":"Neurosurg Focus"},{"issue":"3","key":"10333_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2217\/mmt-2016-0004","volume":"3","author":"AC Olson","year":"2016","unstructured":"Olson AC et al (2016) Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab. Melanoma Manag 3(3):177\u2013186","journal-title":"Melanoma Manag"},{"issue":"1","key":"10333_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijrobp.2017.05.028","volume":"99","author":"NL Williams","year":"2017","unstructured":"Williams NL et al (2017) Phase 1 study of Ipilimumab Combined with Whole Brain Radiation Therapy or Radiosurgery for Melanoma patients with brain metastases. Int J Radiat Oncol Biol Phys 99(1):22\u201330","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10333_CR30","doi-asserted-by":"publisher","first-page":"e1283461","DOI":"10.1080\/2162402X.2017.1283461","volume":"6","author":"T Skrepnik","year":"2017","unstructured":"Skrepnik T et al (2017) Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. Oncoimmunology 6(3):e1283461","journal-title":"Oncoimmunology"},{"issue":"5","key":"10333_CR31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/COC.0000000000000199","volume":"40","author":"KR Patel","year":"2017","unstructured":"Patel KR et al (2017) Ipilimumab and Stereotactic Radiosurgery Versus stereotactic radiosurgery alone for newly diagnosed Melanoma Brain metastases. Am J Clin Oncol 40(5):444\u2013450","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10333_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.radonc.2017.08.009","volume":"125","author":"Y An","year":"2017","unstructured":"An Y et al (2017) Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125(1):80\u201388","journal-title":"Radiother Oncol"},{"issue":"12","key":"10333_CR33","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s00066-018-1356-5","volume":"194","author":"H Schmidberger","year":"2018","unstructured":"Schmidberger H et al (2018) Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters. Strahlenther Onkol 194(12):1144\u20131151","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"10333_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-018-2880-y","volume":"139","author":"K Diao","year":"2018","unstructured":"Diao K et al (2018) Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity. J Neurooncol 139(2):421\u2013429","journal-title":"J Neurooncol"},{"issue":"6","key":"10333_CR35","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3171\/2017.7.JNS171286","volume":"129","author":"K Diao","year":"2018","unstructured":"Diao K et al (2018) Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects. J Neurosurg 129(6):1397\u20131406","journal-title":"J Neurosurg"},{"issue":"2","key":"10333_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11060-019-03379-6","volume":"146","author":"Y Umemura","year":"2020","unstructured":"Umemura Y et al (2020) DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. J Neurooncol 146(2):339\u2013346","journal-title":"J Neurooncol"},{"key":"10333_CR37","doi-asserted-by":"crossref","unstructured":"Ascierto PA et al (2020) Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10\u00a0mg\/kg with 3\u00a0mg\/kg in patients with advanced melanoma. J Immunother Cancer, 8(1)","DOI":"10.1136\/jitc-2019-000391"},{"issue":"1","key":"10333_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11060-019-03363-0","volume":"146","author":"F Martins","year":"2020","unstructured":"Martins F et al (2020) The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study. J Neurooncol 146(1):181\u2013193","journal-title":"J Neurooncol"},{"key":"10333_CR39","doi-asserted-by":"crossref","unstructured":"Borzillo V et al (2021) Ipilimumab and Stereotactic Radiosurgery with CyberKnife(\u00ae) System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. Cancers (Basel), 13(8)","DOI":"10.3390\/cancers13081857"},{"issue":"4","key":"10333_CR40","first-page":"63","volume":"9","author":"K Saginala","year":"2021","unstructured":"Saginala K et al (2021) Epidemiology of Melanoma. Med Sci 9(4):63","journal-title":"Med Sci"},{"issue":"8","key":"10333_CR41","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687\u20131696","journal-title":"Cancer"},{"issue":"2","key":"10333_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11060-015-1932-9","volume":"125","author":"JE Bates","year":"2015","unstructured":"Bates JE et al (2015) Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. J Neurooncol 125(2):411\u2013418","journal-title":"J Neurooncol"},{"issue":"1","key":"10333_CR43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1748-717X-7-77","volume":"7","author":"AV Tallet","year":"2012","unstructured":"Tallet AV et al (2012) Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol 7(1):77","journal-title":"Radiat Oncol"},{"issue":"11","key":"10333_CR44","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.2004.11.044","volume":"22","author":"SS Agarwala","year":"2004","unstructured":"Agarwala SS et al (2004) Temozolomide for the treatment of Brain metastases Associated with metastatic melanoma: a phase II study. J Clin Oncol 22(11):2101\u20132107","journal-title":"J Clin Oncol"},{"issue":"3","key":"10333_CR45","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1177\/107327480901600307","volume":"16","author":"AE Sloan","year":"2009","unstructured":"Sloan AE, Nock CJ, Einstein DB (2009) Diagnosis and treatment of mela-noma brain metastasis: a Literature Review. Cancer Control 16(3):248\u2013255","journal-title":"Cancer Control"},{"issue":"3","key":"10333_CR46","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11060-023-04543-9","volume":"166","author":"JD Tang","year":"2024","unstructured":"Tang JD et al (2024) Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery. J Neurooncol 166(3):431\u2013440","journal-title":"J Neurooncol"},{"key":"10333_CR47","doi-asserted-by":"crossref","unstructured":"Davies MA et al (2017) Dabrafenib plus trametinib in patients with <\u2009em\u2009>\u2009BRAF <\u2009sup\u2009>\u2009V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. The Lancet Oncology, 18(7): pp. 863\u2013873","DOI":"10.1016\/S1470-2045(17)30429-1"},{"issue":"1","key":"10333_CR48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.18.00204","volume":"37","author":"HM Kluger","year":"2018","unstructured":"Kluger HM et al (2018) Long-term survival of patients with Melanoma with active brain metastases treated with Pembrolizumab on a phase II trial. J Clin Oncol 37(1):52\u201360","journal-title":"J Clin Oncol"},{"issue":"12","key":"10333_CR49","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi HA et al (2021) Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol 22(12):1692\u20131704","journal-title":"Lancet Oncol"},{"issue":"4","key":"10333_CR50","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3348\/kjr.2020.0728","volume":"22","author":"PH Kim","year":"2021","unstructured":"Kim PH et al (2021) Immune Checkpoint inhibitor with or without Radiotherapy in Melanoma patients with brain metastases: a systematic review and Meta-analysis. Korean J Radiol 22(4):584\u2013595","journal-title":"Korean J Radiol"},{"issue":"7","key":"10333_CR51","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s11547-022-01503-7","volume":"127","author":"V Lancellotta","year":"2022","unstructured":"Lancellotta V et al (2022) The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review. Radiol Med 127(7):773\u2013783","journal-title":"Radiol Med"},{"issue":"3","key":"10333_CR52","first-page":"326","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail DF, Joyce JA (2017) Microenvironmental Landsc Brain Tumors Cancer Cell 31(3):326\u2013341","journal-title":"Microenvironmental Landsc Brain Tumors Cancer Cell"},{"issue":"18","key":"10333_CR53","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1200\/JCO.2005.07.144","volume":"23","author":"Y Cao","year":"2005","unstructured":"Cao Y et al (2005) Use of magnetic resonance imaging to assess blood-brain\/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 23(18):4127\u20134136","journal-title":"J Clin Oncol"},{"key":"10333_CR54","doi-asserted-by":"publisher","first-page":"175883401774257","DOI":"10.1177\/1758834017742575","volume":"10","author":"T Walle","year":"2018","unstructured":"Walle T et al (2018) Radiation effects on antitumor immune responses: current perspectives and challenges. Ther Adv Med Oncol 10:1758834017742575","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10333_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3171\/2015.6.JNS142763","volume":"125","author":"RJ Colaco","year":"2016","unstructured":"Colaco RJ et al (2016) Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg 125(1):17\u201323","journal-title":"J Neurosurg"},{"issue":"6","key":"10333_CR56","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/CAD.0000000000000497","volume":"28","author":"O Kaidar-Person","year":"2017","unstructured":"Kaidar-Person O et al (2017) The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy. Anticancer Drugs 28(6):669\u2013675","journal-title":"Anticancer Drugs"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10333-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10333-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10333-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T10:04:18Z","timestamp":1745402658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10333-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["10333"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10333-6","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is deemed to exempt to received ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}